Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
EM Jansen, HW Frijlink, WLJ Hinrichs… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Injected mRNA vaccines have been proven effective and safe in the SARS-CoV-
2 pandemic. Using the machinery of the cell, mRNA vaccines translate into an antigen …
2 pandemic. Using the machinery of the cell, mRNA vaccines translate into an antigen …
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2
O Nickel, A Rockstroh, J Wolf, S Landgraf, S Kalbitz… - PLoS one, 2022 - journals.plos.org
Background The currently used SARS-CoV-2 mRNA vaccines have proven to induce a
strong and protective immune response. However, functional relevance of vaccine …
strong and protective immune response. However, functional relevance of vaccine …
Serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with inflammatory bowel disease on biologic therapies
M Shehab, F Alrashed, A Alfadhli, K Alotaibi, A Alsahli… - Vaccines, 2021 - mdpi.com
Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory
bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to …
bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to …
Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation
F Lucca, V Bezzerri, E Danese, D Olioso… - International Journal of …, 2023 - mdpi.com
Cystic fibrosis (CF) is characterized by a progressive decline in lung function, which may be
further impaired by viral infections. CF is therefore considered a comorbidity of coronavirus …
further impaired by viral infections. CF is therefore considered a comorbidity of coronavirus …
Immunogenicity of BNT162b2 vaccine in patients with inflammatory bowel disease on infliximab combination therapy: a multicenter prospective study
Background: Vaccination is a promising strategy to protect vulnerable groups like
inflammatory bowel disease (IBD) patients against COVID-19 and associated severe …
inflammatory bowel disease (IBD) patients against COVID-19 and associated severe …
Antibody response in elderly vaccinated four times with an mRNA anti-COVID-19 vaccine
A Rouvinski, A Friedman, S Kirillov, JH Attal… - Scientific Reports, 2023 - nature.com
The humoral response after the fourth dose of a mRNA vaccine against COVID-19 has not
been adequately described in elderly recipients, particularly those not exposed previously to …
been adequately described in elderly recipients, particularly those not exposed previously to …
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an …
M Rizzi, S Tonello, C Brinno, E Zecca… - Frontiers in …, 2023 - frontiersin.org
Background A relevant proportion of immunocompromised patients did not reach a
detectable seroconversion after a full primary vaccination cycle against SARS-CoV-2. The …
detectable seroconversion after a full primary vaccination cycle against SARS-CoV-2. The …
High incidence of SARS-CoV-2 variant of concern breakthrough infections despite residual humoral and cellular immunity induced by BNT162b2 vaccination in …
B Calcoen, N Callewaert, A Vandenbulcke, W Kerstens… - Viruses, 2022 - mdpi.com
To mitigate the massive COVID-19 burden caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), several vaccination campaigns were initiated. We performed a …
coronavirus 2 (SARS-CoV-2), several vaccination campaigns were initiated. We performed a …
[HTML][HTML] Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
E Anastasi, M Marziali, A Preziosi, E Berardelli… - Microbes and …, 2022 - Elsevier
One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many
people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia …
people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia …
Anti-SARS-CoV-2 IgM Secondary Response Was Suppressed by Preexisting Immunity in Vaccinees: A Prospective, Longitudinal Cohort Study over 456 Days
QY Xu, L Xie, XQ Zheng, XM Liang, ZJ Jia, YY Liu… - Vaccines, 2023 - mdpi.com
To obtain more insight into IgM in anti-SARS-CoV-2 immunity a prospective cohort study
was carried out in 32 volunteers to longitudinally profile the kinetics of the anti-SARS-CoV-2 …
was carried out in 32 volunteers to longitudinally profile the kinetics of the anti-SARS-CoV-2 …